tbuckley/cabot-search huggingface dataset:
Identification and differentiation of Panax ginseng, Panax quinquefolium, and Panax notoginseng by monitoring multiple diagnostic chemical markers
Authors: Wenzhi Yang, Xue Qiao, Kai Li, Jingran Fan, Tao Bo, De-an Guo, Min Ye
Journal: Acta Pharmaceutica Sinica B (2016)

To differentiate traditional Chinese medicines (TCM) derived from congeneric species in TCM compound preparations is usually challenging. The roots of Panax ginseng (PG), Panax quinquefolium (PQ) and Panax notoginseng (PN) are used as popular TCM. They contain similar triterpenoid saponins (ginsenosides) as the major bioactive constituents. Thus far, only a few chemical markers have been discovered to differentiate these three species. Herein we present a multiple marker detection approach to effectively differentiate the three Panax species, and to identify them in compound preparations. Firstly, 85 batches of crude drug samples (including 32 PG, 30 PQ, and 23 PN) were analyzed by monitoring 40 major ginsenosides in the extracted ion chromatograms (EICs) using a validated LC-MS fingerprinting method. Secondly, the samples were clustered into different groups by pattern recognition chemometric approaches using PLS-DA and OPLS-DA models, and 17 diagnostic chemical markers were discovered. Aside from the previously known Rf and p-F11, ginsenoside Rs1 could be a new marker to differentiate PG from PQ. Finally, the above multiple chemical markers were used to identify the Panax species in 60 batches of TCM compound preparations.
Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in <i>BRAF</i>-Mutant Colorectal Cancer
Authors: Daniele Oddo, Erin M. Sennott, Ludovic Barault, Emanuele Valtorta, Sabrina Arena, Andrea Cassingena, Genny Filiciotto, Giulia Marzolla, Elena Elez, Robin M.J.M. van Geel, Alice Bartolini, Giovanni Crisafulli, Valentina Boscaro, Jason T. Godfrey, Michela Buscarino, Carlotta Cancelliere, Michael Linnebacher, Giorgio Corti, Mauro Truini, Giulia Siravegna, Julieta Grasselli, Margherita Gallicchio, René Bernards, Jan H.M. Schellens, Josep Tabernero, Jeffrey A. Engelman, Andrea Sartore-Bianchi, Alberto Bardelli, Salvatore Siena, Ryan B. Corcoran, Federica Di Nicolantonio
Journal: Cancer Research (2016)

Although recent clinical trials of BRAF inhibitor combinations have demonstrated improved efficacy in BRAF-mutant colorectal cancer, emergence of acquired resistance limits clinical benefit. Here, we undertook a comprehensive effort to define mechanisms underlying drug resistance with the goal of guiding development of therapeutic strategies to overcome this limitation. We generated a broad panel of BRAF-mutant resistant cell line models across seven different clinically relevant drug combinations. Combinatorial drug treatments were able to abrogate ERK1/2 phosphorylation in parental-sensitive cells, but not in their resistant counterparts, indicating that resistant cells escaped drug treatments through one or more mechanisms leading to biochemical reactivation of the MAPK signaling pathway. Genotyping of resistant cells identified gene amplification of EGFR, KRAS, and mutant BRAF, as well as acquired mutations in KRAS, EGFR, and MAP2K1 These mechanisms were clinically relevant, as we identified emergence of a KRAS G12C mutation and increase of mutant BRAF V600E allele frequency in the circulating tumor DNA of a patient at relapse from combined treatment with BRAF and MEK inhibitors. To identify therapeutic combinations capable of overcoming drug resistance, we performed a systematic assessment of candidate therapies across the panel of resistant cell lines. Independent of the molecular alteration acquired upon drug pressure, most resistant cells retained sensitivity to vertical MAPK pathway suppression when combinations of ERK, BRAF, and EGFR inhibitors were applied. These therapeutic combinations represent promising strategies for future clinical trials in BRAF-mutant colorectal cancer. Cancer Res; 76(15); 4504-15. ©2016 AACR.
PCM-12MORPHINE IMPROVES EFFICACY OF CHEMOTHERAPY IN AN INTRACRANIAL XENOGRAFT MODEL OF HUMAN GLIOBLASTOMA
Authors: Martina Da Ros, Anna Lisa Iorio, Maurizio Lucchesi, Milena Guidi, Carla Fonte, Claudio Favre, Lorenzo Genitori, Iacopo Sardi
Journal: Neuro-Oncology (2016)
The Cytology of Rabbit Papillomas and Derived Carcinomas&lt;xref ref-type="fn" rid="FN1"&gt;2&lt;/xref&gt;
Authors: Catherine Gardella Palmer, Ph.D.
Journal: JNCI Journal of the National Cancer Institute (1959)

The cytology of rabbit papillomas and of three transplantable tumor lines that originated from these papillomas has been studied in material grown in New Zealand white rabbits. The rabbit papillomas are largely diploid. The carcinomas differ from the papillomas, and from each other, in that the Vx2 carcinoma is hyperdiploid, the V2 carcinoma is triploid, and the Vx7 is a higher polyploid. Possible reasons for these differences are discussed.
Prognostic Factors Affecting Progression Free Survival For Multiple Myeloma Patients Receiving Lenalidomide Maintenance After Autologous Transplantation. Follow-Up Analysis Of The IFM 2005-02 Trial
Authors: Gerald Marit, Valérie Lauwers-Cances, Denis Caillot, Thierry Facon, Cyrille Hulin, Philippe Moreau, Claire Mathiot, Murielle Roussel, Catherine Payen, Pascale Olivier, Hervé Avet-Loiseau, Michel Attal
Journal: Blood (2013)
Treatment opportunities on a consultation/liaison service
Authors: J S Lyons, J S Hammer, D B Larson, J Petraitis, J J Strain
Journal: American Journal of Psychiatry (1988)

The amount of time consultation psychiatrists in a large metropolitan teaching hospital spent providing direct services was studied over 1,104 consecutive consultation cases. Although the majority of cases required less than 5 hours of psychiatric time apiece, more than 10% of these cases each received more than 10 hours of direct services. This finding has important implications for understanding the types of psychiatric services provided to hospitalized medical/surgical patients.
Soundings: The quest
Authors: Liam Farrell
Journal: BMJ (2004)

“I have a mighty task for you,” said Gandalf. “The Dark Tower is rebuilt; orcs are multiplying like rabbits (they have no concept of responsible birth control), hobbits are being forced to get proper jobs instead of lying around drunk all the time, and flocks of confused Nazgul are terrorizing Narnia. The Dark Lord has awakened; he is seeking... the Ring.”

“What ring?” I said.

“This one,” he said, palming it from behind my ear. “Though quite nice to look at, it corrupts the owner; they become hard and cynical and develop halitosis and crumbly fingernails.”

He took out a pipe and blew a magical smoke ring in the shape of a jewelled speculum. I absent-mindedly tapped a computer key for “Smoker,” told him that he should give up, and tapped another key for “Smoking cessation advice given.” “The elves have a saying,” he continued. “'When in doubt, call the GP,' and since ye are hard and cynical anyway the Ring can't make you any worse. It must be destroyed, and you must take it to the fires of Mount Doom, which inconveniently is right beside the Dark Tower; you may take any loyal assistant of your choice.”

“Could I have Lassie?” I asked.

“No problem,” he said, taking out a little book rather discouragingly titled Easy Spells for SHOs. There was a puff of smoke, Lassie burst joyfully into the room, snuggled into my lap, and licked my hand, then tried to bite the ring and turned into a small, bewildered, drug rep who burst into tears, glad-handed us some promotional pens, and fled.

“Why not just hop on one of those big eagles?'” I suggested. “Fly down, chuck it in, and you'd be back before the Dark Lord could say, `Galadriel is a cheap slut'.”

“Alas,” Gandalf explained vaguely, deftly pocketing the pens, “Alack.”

“All right,” I said, “I'll get rid of it.”

“The Seven Fairies shall sing your praises,” he said, getting up hastily to leave. “By the way, can I have an antibiotic? I've an awful cou-...” I closed the door firmly, accidentally crushing a dwarf, and eyed the Ring speculatively. Thin spidery writing appeared on it, ancient elvish runes, which roughly translated as “Legolas fancies Aragorn.” “From where I'm sending you, buddy, you ain't never coming back,” I said, popping the Ring in an envelope, addressing it to the local neurology outpatients, and marking it “non-urgent.”
Case 37-1984
Authors: Richard C. Cabot, Robert E. Scully, Eugene J. Mark, Betty U. McNeely
Journal: New England Journal of Medicine (1984)

Presentation of Case A 31-year-old woman was admitted to the hospital because of virilization. The patient's menarche occurred at the age of 12 years, with regular menses every 28 days. When she was 19 years of age her first child was delivered uneventfully, and she returned to her previous weight of 56.8 kg, with monthly menstrual periods that lasted three to four days. After the birth of her second child at the age of 20 years her weight remained at 68.2 kg, and it gradually increased during the next 10 years. Regular menses resumed; the patient began to use an . . .
The<i>Journal</i>'s Peer-Review Process
Journal: New England Journal of Medicine (1989)

LIKE many other scientific journals, the New England Journal of Medicine must select the material it will publish from a large number of manuscripts submitted each year. Those ultimately selected usually undergo substantial revision before publication. The process of selection and revision is probably unfamiliar to most readers, because it involves confidential transactions between editors, authors, and outside experts (called reviewers or referees). The following brief description is intended to explain how the Journal approaches its task.The Journal receives about 3600 unsolicited manuscripts yearly. Roughly two thirds of these are reports of original scientific research, a few are reviews . . .
&lt;TITLE&gt;Heart Disease and Women&lt;/TITLE&gt;
Authors: Janet M Torpy, Cassio Lynm, Richard M Glass
Journal: JAMA (2002)

Heart Disease and Women Heart disease kills more women each year in the United States than any other medical problem.Heart disease takes the lives of more women in the United States than stroke, breast cancer, ovarian or uterine cancer, and HIV combined.Women may have fewer or different heart disease symptoms than men have, until the heart disease is far advanced.The most common form of heart disease, coronary heart disease (blockage of the coronary arteries, the heart' s blood supply), is often preventable.The December 25, 2002, issue of JAMA includes an article about treatment of heart attacks and angina (heart-related pain) in women.
AT-06THE EXTRAORDINARY CHALLENGE OF TREATING PATIENTS WITH CONGENITAL RHABDOID TUMORS - DATA FROM FRANCE, RUSSIA AND THE EU-RHAB REGISTRY
Authors: Michael Frühwald, Denis Kachanov, Monica Zlatic, Nathalie Clement, Tatyana Shamaskaya, Svetlana Varfolomeeva, Reinhard Schneppenheim, Reiner Siebert, Joachim Gerss, Martin Hasselblatt, Franck Bourdeaut
Journal: Neuro-Oncology (2016)
Effect of a Bacterial Polysaccharide and of Several Other Tumor-Necrotizing Agents on Carotid Blood Pressure in Mice&lt;xref ref-type="fn" rid="FN1"&gt;2&lt;/xref&gt;
Authors: Murray J. Shear, Betty Achinstein, Sachindra N. Pradhan
Journal: JNCI Journal of the National Cancer Institute (1958)

The effect of several tumor-necrotizing agents on systemic blood pressure in mice was studied by a method that permitted continuous recording of pressure directly from the carotid artery. The polysaccharide from Serratia marcescens did not depress the blood pressure immediately. When the continuous recording was prolonged for hours, a gradual fall of blood pressure was observed in the control as well as in the treated mice. However, when the recording was limited to a half-hour period a significant fall was not produced within the first 6 hours after administration of polysaccharide. Analogously, the tracings obtained in mice treated with podophyllotoxin, colchicine, and several of their derivatives showed no evidence of induced fall of blood pressure on comparison with the tracings yielded by the controls. The production by these drugs of a sustained systemic hypotension, which had been postulated as a necessary prerequisite for their elicitation of hemorrhagic necrosis in tumors, is not supported by this study.
EPT-19PHASE I TRIAL OF PALBOCICLIB, A CDK4/6 INHIBITOR IN CHILDREN WITH RETINOBLASTOMA PROTEIN (RB1) + RECURRENT CENTRAL NERVOUS SYSTEM (CNS) TUMORS (PBTC 042)
Authors: Sridharan Gururangan, Oren Becher, Sarah Leary, Arzu Onar-Thomas, Jie Huang, Joanna Phillips, Clinton F. Stewart, Jason Fangusaro, Rishi Lulla, Patricia Baxter, Ian Pollack, James Boyett, Maryam Fouladi
Journal: Neuro-Oncology (2016)
Veliparib monotherapy to patients with BRCA germline mutation and platinum-resistant or partially platinum-sensitive selapse of epithelial ovarian cancer: A phase I/II study.
Authors: Karina Dahl Steffensen, Parvin Adimi, Anders Kristian Moeller Jakobsen
Journal: Journal of Clinical Oncology (2016)

5532 Background: A new treatment principle, which seems to radically change the treatment approach in ovarian cancer has been developed over the last few years. PARP inhibitors work by interfering with mechanisms important to DNA damage repair in cells. Cancer cells that already have defects in the BRCA genes are particularly sensitive to treatment with PARP inhibitors. The main purpose of this study is to investigate the effect of the oral PARP inhibitor Veliparib as single-agent therapy in patients with known BRCA1/2 mutations and with a platinum resistant or intermediate sensitive relapse of ovarian cancer. Methods: Major eligibility criteria were primary epithelial ovarian/fallopian/peritoneal cancer patients with a platinum resistant or intermediate sensitive relapse of ovarian cancer and with measurable disease by either RECIST or GCIG CA125 criteria. Patients were treated with oral Veliparib twice daily on days 1-28 until progression or unacceptable toxicity as part of a phase I/II investigator initiated study. Results: Sixteen patients were enrolled in the phase I part and a maximum tolerable dose of 300 mg twice daily was established. The phase II part enrolled 32 patients with a median of 4 previous treatment regimens. The overall response rate was 65.7 % (6.3 % complete responders and 59.4 % partial responders).Progression-free and overall survival in the intention-to-treat population was 5.5 months (4.9-7.3 months, 95% CI) and 15.2 months (10.0-17.3 months, 95%CI), respectively. The most common treatment related grade 2 toxicities included fatigue (22%), nausea (22%) and vomiting (9%). Conclusions: Treatment with Veliparib in heavily pretreated patients with relapse of ovarian cancer demonstrates considerable efficacy with an acceptable toxicity profile. Clinical trial information: NCT01472783.
Treatment of Plantar Warts
Authors: J LELIEVRE
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
RA-13COMPARISON OF FINAL INTRA-OPERATIVE MR SCAN AND POST-OPERATIVE MRI PERFORMED 24 TO 72 HOURS AFTER BRAIN TUMOUR RESECTION
Authors: Shivaram Avula, Tim Jaspan, Barry Pizer, Benedetta Pettorini, Chris Parks, Conor Mallucci
Journal: Neuro-Oncology (2016)

BACKGROUND: There is no published evidence comparing the utility of final intraoperative MRI (ioMRI) and early post-operative MRI (24-72 hours) as baseline scans following brain tumour resection.AIM: To evaluate the utility and validity of the final ioMRI scan as a post-operative baseline after paediatric brain tumour resections.METHOD: A prospective audit
EPT-15A PHASE1/2 CLINICAL TRIAL OF VELIPARIB (ABT-888) AND RADIATION FOLLOWED BY MAINTENANCE THERAPY WITH VELIPARIB AND TEMOZOLOMIDE (TMZ) IN PATIENTS WITH NEWLY DIAGNOSED DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG): A PEDIATRIC BRAIN TUMOR CONSORTIUM INTERIM REPORT OF PHASE II STUDY
Authors: Patricia Baxter, Jack Su, Xiao-nan Li, Arzu Onar Thomas, Catherine Billups, Patrick Thompson, Tina Poussaint, Evelyn McKeegan, Xia Wan, Peter Ansell, Vincent Giranda, Arnold Paulino, Lindsay Kilburn, Ibrahim Qaddoumi, Alberto Broniscer, Susan Blaney, James Boyett, Maryam Fouladi
Journal: Neuro-Oncology (2016)
Case 24-1987
Authors: Richard C. Cabot, Robert E. Scully, Eugene J. Mark, William F. McNeely, Betty U. McNeely
Journal: New England Journal of Medicine (1987)

Presentation of Case A 56-year-old man was admitted to the hospital because of a substernal goiter. He was well until three or four years earlier, when he began to experience intermittent dyspnea during the night, without cough, wheeze, or hemoptysis. Sixteen months before admission he was first seen at this hospital, where examination showed that the blood pressure was 130/85 mm Hg. He was markedly obese, with clear lungs. The hematocrit was 54 percent, the white-cell count 6300, the hemoglobin 16.1 g per 100 ml, the total eosinophil count 35 per cubic millimeter, and the erythrocyte sedimentation rate 13 mm . . .
Cimetidine-imipramine interaction: a case report
Authors: D D Miller, M Macklin
Journal: American Journal of Psychiatry (1983)

T he histamine H2-neceptor antagonist cimetidine is an effective drug widely prescribed for the treatment of peptic ulcer disease (1). It is also useful in the treatment of gastric ulcers and erosive gastnitis and in the treatment and prevention of stress ulcers (1). It was initially thought that cimetidine had few adverse effects. With increased use cimetidine has been found (1-3) to cause mental confusion, bone marrow depression, and decreased sperm count and to interfere with the metabolism of drugs metabolized by cytochnome P448 and P450. Drugs that are metabolized by these mixed-function oxidase systems with metabolism inhibited by cimetidine are antipynine, warfanin, diazepam, chlordiazepoxide, propranolol, labetalol, theophylline, carbamazepine, and phenytoin (2). These interactions have been shown to have important, sometimes life-threatening, implications. We present a case of cimetidine interfering with imipnamine and desipramine metabolism, resulting in elevated serum concentrations of imipramine and desipnamine and in adverse effects in a patient receiving a usual therapeutic dose of irnipramine.
OP17SUPPORTING CHILDREN AND YOUNG PEOPLE WITH A BRAIN TUMOUR TO RETURN TO SCHOOL: THE CREATION OF AN INNOVATIVE, INTER-AGENCY PATHWAY
Authors: Emily Bennett, Nicki Hammill, Pam White, Louise Robinson
Journal: Neuro-Oncology (2015)

INTRODUCTION: Clinical work and small-scale research with families of children and young people (CYP) diagnosed with a brain tumour (BT) highlighted significant issues with returning to school. The process was often reported to be delayed and extremely stressful for CYP, and families felt schools were frequently underprepared and slow to respond to the CYP's needs. Learning from one young man's experience, in particular, led to discussions about the need for a clear, collaborative return to school pathway and guidance. METHOD: Initial meetings between the local Educational Psychology (EP) service, a YP with a BT and his parents, and the paediatric neuropsychology service at a regional centre, led to plans for the development of a collaborative return to school pathway and guidance document. Contributions were sought from key agencies involved in supporting CYP with a BT, including neuro-oncology keyworkers and teaching staff. RESULTS: A return to school pathway and guidance document was produced. This outlines involvement and responsibilities of key agencies, and provides information for schools around preparing staff, pupils and the environment for the CYP's return. Best practice examples and a school action checklist are included. The document also outlines the respective roles of the EP service, neuropsychologists, and keyworkers in supporting the process. The pathway is now being piloted in the county. CONCLUSION: Concerns about poor return to school experience of many BT patients led to the development of a pathway document for local education services. It aims to build on previous experience and promote collaboration between key agencies to maximise opportunities for CYP with a BT to make a positive return to school.
Shifts in diagnostic frequencies of schizophrenia and major affective disorders at six North American psychiatric hospitals, 1972-1988
Authors: A L Stoll, M Tohen, R J Baldessarini, D C Goodwin, S Stein, S Katz, D Geenens, R P Swinson, J W Goethe, T McGlashan
Journal: American Journal of Psychiatry (1993)

This study tested the impression that there have been significant shifts in the relative diagnostic frequencies of schizophrenia and major affective disorders.Data on discharge diagnoses from 1972 to 1988 were gathered from six North American psychiatric teaching hospitals (data from one extended through 1991), and rates for schizophrenia and major mood disorders were evaluated.Total annual discharges increased by 6.6% during the study period. Large reciprocal shifts in the frequencies of diagnoses of schizophrenia and major affective disorders were found; schizoaffective disorder was a minor diagnosis. Beginning in the early 1970s, a gradual increase in the frequency of diagnoses of major affective disorders at all sites was accompanied by a corresponding decrease in diagnoses of schizophrenia at five of the six centers. Schizophrenia diagnoses decreased from a peak of 27% in 1976 to 9% in 1989 (a threefold decrease), and diagnoses of major affective disorders rose from a low of 10% in 1972 to 44% in 1990 (a fourfold increase).Several forces may have influenced these changes. 1) DSM-III narrowed the definition of schizophrenia and broadened the category of major affective disorders. 2) Treatment-oriented diagnostic bias associated with the availability of lithium and other mood-altering agents may have encouraged consideration of affective disorders. 3) Economic and social forces, including better third-party reimbursement rates, may have favored affective diagnoses. 4) True increases in the incidence of affective disorders may have occurred. 5) Although a real decrease in new cases of schizophrenia may have occurred, this effect was probably minor and dominated by a larger shift of such diagnoses to affective categories.
Imatinib Has a Negative Impact On Growth In Children With Previously Untreated Chronic Myeloid Leukaemia (CML) In Early Chronic Phase (CP): Results Of The French National Study
Authors: Frédéric Millot, Joelle Guilhot, Andre Baruchel, Arnaud Petit, Thierry Leblanc, Yves Bertrand, Françoise Mazingue, Patrick Lutz, Cécile Vérité, Christian Berthou, Claire Galambrun, Nicolas Sirvent, Karima Yacouben, Pascal Chastagner, Virginie Gandemer, Yves Reguerre, Gérard Couillaud, Jean-Michel Cayuela
Journal: Blood (2013)